Ivaltinostat formic

伊伐替司他甲酸

Ivaltinostat formic

I658991-5mg

5mg

≥99%

2-8°C储存,干燥

冰袋运输

Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic Appearance:Oil IC50& Target:HDAC In Vitro:Ivaltinostat (CG-200745; 0.01-100 μM; 48 hours) formic inhibits growth of prostate cancer cells (LNCaP, DU145 and PC3 cells). Ivaltinostat (1, 10 μM; 24, 48 hours) formic increases sub-G1 population, and activates caspase-9, -3 and -8. Ivaltinostat ( In Vivo:Ivaltinostat (CG-200745; p.o.; 30mg/kg/day; for 7 days) formic attenuates oxidative stress, inflammatory cytokines, and adhesion molecules in UUO kidneys. MCE has not independently confirmed the accuracy of these methods. They are for reference only Biological Activity:Ivaltinostat (CG-200745) formic is an orally active, potent pan- HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic

C25H35N3O6

473.56 g/mol

OC=O.O=C(NCCCN(C)C)/C(COC1=C2C=CC=CC2=CC=C1)=C/CCCCC(NO)=O

DMSO : 50 mg/mL (105.58 mM; Need ultrasonic) H2O : 50 mg/mL (105.58 mM; Need ultrasonic)